Taken together, the present study demonstrates that miR-422a may serve as a tumor suppressor in osteosarcoma via inhibiting BCL2L2 and KRAS translation both <i>in vitro</i> and <i>in vivo</i> Therefore, miR-422a could be developed as a novel therapeutic target in osteosarcoma.
A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.